Goldman Sachs Group Inc Essa Pharma Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	BUY	$1.75 - $3.44 $22,386 - $44,004	12,792 Added 108.97%	24,531 $45,000
Q3 2022 Nov 10, 2022	BUY	$1.75 - $3.44 $22,386 - $44,004	12,792 Added 108.97%	24,531 $0
Q2 2022 May 14, 2024	BUY	$3.15 - $7.94 $36,977 - $93,207	11,739 New	11,739 $37,000
Q2 2022 Aug 15, 2022	SELL	$3.15 - $7.94 $206,095 - $519,490	-65,427 Reduced 84.79%	11,739 $37,000
Q1 2022 May 16, 2022	SELL	$6.18 - $14.44 $106,444 - $248,714	-17,224 Reduced 18.25%	77,166 $477,000
Q4 2021 Feb 14, 2022	SELL	$7.8 - $14.38 $212,245 - $391,294	-27,211 Reduced 22.38%	94,390 $1.34 Million
Q3 2021 Nov 10, 2021	BUY	$7.76 - $29.37 $943,623 - $3.57 Million	121,601 New	121,601 $973,000

35.1M

15.8K

21K

Ticker EPIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,073,100
Market Cap $75.4M
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreem...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.